Tag - MRNS

Marinus Pharma

Ladenburg starts Marinus Pharma at buy; PT $20

Ladenburg Thalmann launched coverage of Marinus Pharmaceuticals (NASDAQ:MRNS) with a “buy” rating and $20 price target. The stock closed at $6.74 on June 5. Marinus is developing ganaxolone (GNX), a synthetic analog of...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.